11/21
04:18 am
cccc
Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
Low
Report
Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]
11/20
07:07 am
cccc
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
Medium
Report
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]
11/20
07:00 am
cccc
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Medium
Report
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
11/18
08:50 am
cccc
C4 Therapeutics, Inc. (NASDAQ: CCCC) is now covered by analysts at Stephens. They set an "equal weight" rating and a $4.00 price target on the stock.
Medium
Report
C4 Therapeutics, Inc. (NASDAQ: CCCC) is now covered by analysts at Stephens. They set an "equal weight" rating and a $4.00 price target on the stock.
11/6
07:00 am
cccc
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
Medium
Report
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
11/5
09:00 am
cccc
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
Medium
Report
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
10/31
07:00 am
cccc
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Medium
Report
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
10/28
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/15
04:15 pm
cccc
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. [Yahoo! Finance]
High
Report
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. [Yahoo! Finance]
10/15
04:01 pm
cccc
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
High
Report
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
10/9
07:00 am
cccc
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
Low
Report
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
9/30
04:01 pm
cccc
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/13
10:00 am
cccc
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Medium
Report
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
9/10
07:00 am
cccc
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
High
Report
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
9/8
06:17 pm
cccc
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 [Yahoo! Finance]
Medium
Report
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 [Yahoo! Finance]
9/8
06:05 pm
cccc
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
Medium
Report
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
9/3
07:00 am
cccc
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
Medium
Report
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
8/29
07:00 am
cccc
C4 Therapeutics to Participate in Upcoming September Investor Conferences
Low
Report
C4 Therapeutics to Participate in Upcoming September Investor Conferences